-
1
المؤلفون: Jong, E.J.M. de, Janssen, Q.P., Simons, T.F.A., Besselink, M.G., Bonsing, B.A., Bouwense, S.A.W., Geurts, S.M.E., Homs, M.Y.V., Meijer, V.E. de, Tjan-Heijnen, V.C.G., Laarhoven, H.W.M. van, Valkenburg-van Iersel, L.B.J., Wilmink, J.W., Geest, L.G. van der, Koerkamp, B.G., Vos-Geelen, J. de, Dutch Pancreatic Canc Grp
المساهمون: RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Heelkunde (9), MUMC+: MA Medische Oncologie (9), Medical Oncology, Surgery, CCA - Cancer Treatment and Quality of Life, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Oncology, Center for Liver, Digestive and Metabolic Diseases (CLDM), Groningen Institute for Organ Transplantation (GIOT), Internal medicine, VU University medical center
المصدر: the Dutch Pancreatic Cancer Group 2021, ' Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma ', International Journal of Cancer . https://doi.org/10.1002/ijc.33916
International Journal of Cancer, 150(10), 1654-1663. Wiley
International Journal of Cancer, 150(10), 1654-1663. WILEY
International Journal of Cancer, 150(10), 1654-1663. Wiley-Liss Inc.
International Journal of Cancer. Wiley-Liss Inc.مصطلحات موضوعية: Cancer Research, RESECTION, endocrine system diseases, pancreatic cancer, MULTICENTER, PHASE-III TRIAL, CHEMOTHERAPY, OPEN-LABEL, Deoxycytidine, Gemcitabine, CANCER, THERAPY, TRENDS, Pancreatic Neoplasms, FOLFIRINOX, Oncology, SDG 3 - Good Health and Well-being, Chemotherapy, Adjuvant, Antineoplastic Combined Chemotherapy Protocols, SURVIVAL, Humans, Capecitabine, Carcinoma, Pancreatic Ductal
وصف الملف: application/pdf
-
2
المؤلفون: Versteijne, E., Dam, J.L. van, Suker, M., Janssen, Q.P., Groothuis, K., Akkermans-Vogelaar, J.M., Besselink, M.G., Bonsing, B.A., Buijsen, J., Busch, O.R., Creemers, G.J.M., Dam, R.M. van, Eskens, F.A.L.M., Festen, S., Groot, J.W.B. de, Koerkamp, B.G., Hingh, I.H. de, Homs, M.Y.V., Hooft, J.E. van, Kerver, E.D., Luelmo, S.A.C., Neelis, K.J., Nuyttens, J., Paardekooper, G.M.R.M., Patijn, G.A., Sangen, M.J.C. van der, Vos-Geelen, J. de, Wilmink, J.W., Zwinderman, A.H., Punt, C.J., Tienhoven, G. van, Eijck, C.H.J. van, Dutch Pancreatic Canc Grp
المساهمون: Surgery, Medical Oncology, Radiotherapy, CCA - Cancer Treatment and Quality of Life, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Gastroenterology and Hepatology, Oncology, Epidemiology and Data Science, APH - Methodology, Radiation Oncology, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Radiotherapie, MUMC+: MA Heelkunde (9), Interne Geneeskunde, MUMC+: MA Medische Oncologie (9)
المصدر: Journal of Clinical Oncology, 40(11), 1220-1230. American Society of Clinical Oncology
Versteijne, E, van Dam, J L, Suker, M, Janssen, Q P, Groothuis, K, Akkermans-Vogelaar, J M, Besselink, M G, Bonsing, B A, Buijsen, J, Busch, O R, Creemers, G-J M, van Dam, R M, Eskens, F A L M, Festen, S, de Groot, J W B, Groot Koerkamp, B, de Hingh, I H, Homs, M Y V, van Hooft, J E, Kerver, E D, Luelmo, S A C, Neelis, K J, Nuyttens, J, Paardekooper, G M R M, Patijn, G A, van der Sangen, M J C, de Vos-Geelen, J, Wilmink, J W, Zwinderman, A H, Punt, C J, van Tienhoven, G & van Eijck, C H J 2022, ' Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer : Long-Term Results of the Dutch Randomized PREOPANC Trial ', Journal of Clinical Oncology, vol. 40, no. 11, pp. 1220-1230 . https://doi.org/10.1200/JCO.21.02233
Journal of Clinical Oncology, 40(11), 1220-+. LIPPINCOTT WILLIAMS & WILKINS
Journal of clinical oncology, 40(11), 1220-1230. American Society of Clinical Oncologyمصطلحات موضوعية: Cancer Research, MULTICENTER, ADENOCARCINOMA, Chemoradiotherapy, OPEN-LABEL, THERAPY, TRENDS, Neoadjuvant Therapy, Pancreatic Neoplasms, Survival Rate, CHEMORADIATION, ADJUVANT CHEMOTHERAPY, Oncology, GEMCITABINE, SDG 3 - Good Health and Well-being, Antineoplastic Combined Chemotherapy Protocols, Humans
وصف الملف: application/pdf
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0c80077a065c4bb8306a86eb726545e
http://www.scopus.com/inward/record.url?scp=85125798289&partnerID=8YFLogxK -
3
المؤلفون: Sijde, F. van der, Dik, W.A., Mustafa, D.A.M., Vietsch, E.E., Besselink, M.G., Debets, R., Koerkamp, B.G., Haberkorn, B.C.M., Homs, M.Y.V., Janssen, Q.P., Luelmo, S.A.C., Mekenkamp, L.J.M., Oostvogels, A.A.M., Nijenhuis, M.A.W.S.T., Wilmink, J.W., Eijck, C.H.J. van
المساهمون: Surgery, Immunology, Pathology, Medical Oncology, CCA - Cancer Treatment and Quality of Life, Amsterdam Gastroenterology Endocrinology Metabolism, Oncology, CCA - Cancer biology and immunology
المصدر: Frontiers in Immunology, 13:898498. Frontiers Media S.A.
Frontiers in immunology, 13:898498. Frontiers Media S.A.
Frontiers in Immunology, 13. FRONTIERS MEDIA SAمصطلحات موضوعية: Interleukin-7, pancreatic cancer, Immunology, Interleukin-18, Leucovorin, treatment response, Irinotecan, Oxaliplatin, Pancreatic Neoplasms, Interleukin 1 Receptor Antagonist Protein, IL-1RA, SDG 3 - Good Health and Well-being, Antineoplastic Combined Chemotherapy Protocols, cytokine, Cytokines, Humans, biomarker, Immunology and Allergy, Fluorouracil, Chemokine CCL4, Carcinoma, Pancreatic Ductal
وصف الملف: application/pdf
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::493dbacff71760bbb74091a085213bbc
https://doi.org/10.3389/fimmu.2022.898498 -
4دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
5دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
6دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
7دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
8دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
9دورية أكاديمية
المؤلفون: Groot Koerkamp, B., Janssen, Q.P., van Dam, J.L., Bonsing, B.A., Bos, H., Bosscha, K.P., Haberkorn, B.C.M., de Hingh, I.H.J.T., Karsten, T.M., Van der Kolk, M.B., Liem, M.S.L., Loosveld, O.J.L., Patijn, G.A., van Santvoort, H.C.M., J. de vos-Geelen, van der Holt, B., Homs, M.Y.V., van Tienhoven, G., Besselink, M.G., Wilmink, H.W.
المصدر: In Annals of Oncology October 2023 34 Supplement 2:S1323-S1323
-
10
المؤلفون: Janssen, Q.P., Dam, J.L. van, Bonsing, B.A., Bos, H., Bosscha, K.P., Coene, P.P.L.O., Eijck, C.H.J. van, Hingh, I.H.J.T. de, Karsten, T.M., Kolk, M.B. van der, Patijn, G.A., Liem, M.S.L., Santvoort, H.C. van, Loosveld, O.J.L., Vos-Geelen, J. de, Zonderhuis, B.M., Homs, M.Y.V., Tienhoven, G. van, Besselink, M.G., Wilmink, J.W., Koerkamp, B.G., Dutch Pancreatic Canc Grp
المساهمون: Surgery, AGEM - Re-generation and cancer of the digestive system, CCA - Cancer Treatment and quality of life, Radiation Oncology, Radiotherapy, CCA - Cancer Treatment and Quality of Life, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Oncology, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Medical Oncology
المصدر: BMC Cancer
BMC Cancer, 21(1):300. BioMed Central
BMC cancer, 21(1):300. BioMed Central
BMC Cancer, 21(1):300. BioMed Central Ltd
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
Dutch Pancreatic Cancer Group 2021, ' Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial) : study protocol for a nationwide multicenter randomized controlled trial ', BMC Cancer, vol. 21, no. 1, 300 . https://doi.org/10.1186/s12885-021-08031-z
BMC Cancer, 21(1). BMC
BMC Cancer, 21(1):300. BioMed Central Ltd.مصطلحات موضوعية: Oncology, Quality of life, Cancer Research, medicine.medical_specialty, FOLFIRINOX, medicine.medical_treatment, Leucovorin, Irinotecan, lcsh:RC254-282, Deoxycytidine, 03 medical and health sciences, Study Protocol, 0302 clinical medicine, SDG 3 - Good Health and Well-being, Internal medicine, Pancreatic cancer, Antineoplastic Combined Chemotherapy Protocols, Genetics, medicine, Clinical endpoint, Humans, Overall survival, 030212 general & internal medicine, Neoadjuvant therapy, Randomized Controlled Trials as Topic, business.industry, Localized pancreatic cancer, Chemoradiotherapy, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, Gemcitabine, Neoadjuvant Therapy, Oxaliplatin, Pancreatic Neoplasms, Intention-to-treat, Randomized controlled trial, 030220 oncology & carcinogenesis, Folfirinox Regimen, Fluorouracil, Neoadjuvant, business, medicine.drug
وصف الملف: application/pdf
Find this article in full text from Springer Verlag.